How Are the Responsibilities of an Authorized Representative Divided for Medical Device Registration in Canada?

How Are the Responsibilities of an Authorized Representative Divided for Medical Device Registration in Canada?

The authorized representative (AR) is the statutory contact for foreign manufacturers in Canada, bearing core responsibilities such as product registration, post-market surveillance, adverse event reporting, and recall coordination. The division of responsibilities is governed by the agreement between the manufacturer and the AR and by the Canadian Medical Devices Regulations (CMDR). Manufacturers must first confirm whether their product falls under Health Canada's jurisdiction, then determine the registration pathway based on risk class (Class I–IV): Class I only requires an ISO 13485 quality system and submission of an establishment license; Class II–IV require a Medical Device License (MDL) and may require MDSAP certification. The AR is responsible for submitting registration applications, maintaining technical documentation (including risk management, clinical evaluation, labeling), handling communications with Health Canada, and facilitating inspections.

Scope and Core Issues

This guidance applies to all foreign manufacturers planning to export medical devices to Canada, regardless of product risk class. The core issue is: what specific responsibilities does the AR assume during Canadian registration? How can manufacturers ensure clear division of responsibilities in compliance with Health Canada requirements? The AR is not merely a contact person but a legal entity that bears joint liability for the product's lawful marketing and ongoing compliance.

Registration Decision Logic

Step 1: Confirm whether the product is a medical device under CMDR

Products that meet the definition of a medical device (e.g., for diagnosis, treatment, alleviation of disease) require registration; certain low-risk products (e.g., some laboratory reagents) may be exempt, but each case must be verified individually.

Step 2: Determine the risk class

Class I (lowest risk) requires only a quality system and establishment license, no MDL; Class II–IV require an MDL, with Class III/IV requiring clinical evidence. Risk class directly affects the registration pathway and the depth of AR responsibilities.

Step 3: Assess existing quality system and technical documentation for reuse

If manufacturers already have NMPA, CE, FDA, or MDSAP certification, some documents (e.g., risk management reports, performance test data) may be transferable, but a gap analysis against CMDR is needed. For example, Canada requires labeling in English and French, and clinical evaluation must meet CMDR standards for effectiveness and safety.

Step 4: Define AR responsibilities in the agreement

The agreement should clearly specify that the AR is responsible for: submitting registration applications, maintaining technical files, receiving inspection notifications from Health Canada, reporting adverse events, executing recalls, and updating registration information (e.g., address changes). The manufacturer retains ownership and updating obligations for the technical documentation.

Documents and Evidence

Manufacturers need to prepare the following core documents for the AR to submit or for reference:

• Quality system certificate (ISO 13485 or MDSAP certification; MDSAP is more advantageous for Canadian registration)
• Product technical documentation: including product description, design documents, risk management report (ISO 14971), performance verification (e.g., electrical safety, biocompatibility, stability tests)
• Clinical evaluation data: Class III/IV require clinical evidence; existing literature or clinical trial data may be cited, and must comply with CMDR clinical evaluation guidelines
• Labels and instructions for use: in English and French, covering intended use, contraindications, warnings, instructions, and must be consistent with registration information
• Authorized representative agreement: clearly defining responsibilities, fees, termination terms, data confidentiality, and handover arrangements
• Letter of Authorization: signed by the manufacturer, designating the AR as the statutory contact

Common Risks and Errors

• Inadequate AR qualifications: Choosing a "virtual agent" that offers only regulatory consulting compliance but lacks a physical address and actual regulatory response capability, making it impossible for Health Canada to effectively contact.
• Unclear responsibility boundaries: The agreement fails to detail change management, adverse event reporting timelines, cost bearing, etc., leading to disputes when problems arise.
• Technical documentation not localized for CMDR: Directly reusing CE or FDA documents while ignoring Canada-specific requirements (e.g., bilingual labels, different clinical evidence standards).
• Neglecting post-market surveillance responsibilities: The AR fails to establish adverse event collection and reporting processes, violating MDR reporting requirements.
• Missing renewal and change management: MDL or establishment license expires without timely renewal, or product changes are not communicated to the AR, resulting in loss of registration validity.

Manufacturer Preparation Checklist

Before initiating a project, manufacturers should use an internal checklist to confirm document readiness:

• Compile target product list, model specifications matrix, and intended use statements.
• Check existing registration documents from NMPA, CE, FDA, or other markets for reuse potential.
• Prepare ISO 13485 certificate, test reports, risk management documents, clinical evaluation, and English instructions for use.
• Confirm the local agent or AR's responsibilities, fees, certificate control rights, and exit mechanism.
• Establish a gap assessment table for the target country, identifying tests, translations, notarizations, or supplementary statements needed.

AIMEILI Regulatory Interpretation and Business Impact

Manufacturers often mistakenly believe that the AR is merely a "document intermediary," ignoring its legal status as a statutory responsible party. Many small and medium manufacturers choose low-cost agents, but when a product recall or adverse event occurs, an underqualified agent cannot respond effectively, leading directly to penalties or market access barriers. In the early stages of a project, priority should be given to evaluating the AR's actual capabilities: Does it have a physical office? Is it familiar with CMDR and MDSAP? Can it provide drug or medical device quality consulting?

For document reuse, MDSAP certification is a mutually recognized quality system among Canada, the United States, Brazil, Japan, and Australia. Obtaining MDSAP in advance can significantly reduce additional work for Canadian registration. Among technical documents, risk management reports (ISO 14971) and clinical evaluation are major pain points. Canada's acceptance of clinical evidence is more flexible than FDA's, but requires a clear literature search strategy and a benefit-risk analysis. For localization, bilingual labels in English and French must be translated by a professional translation agency with a translation certificate retained.

Regarding agent and certificate control rights, manufacturers are advised to directly hold ownership of registration certificates (e.g., MDL), with the AR acting only as a contact person. Change and renewal cannot be fully delegated to the agent; manufacturers must establish internal tracking mechanisms. For multi-country registrations, it is recommended to first build an MDSAP system and then supplement localization for each country's differences, reducing the risk of duplicate preparation and correction requests.

Frequently Asked Questions (FAQs)

Must the authorized representative be a non-Canadian entity?
No. The authorized representative must be an individual or company with a physical address in Canada. It can be a branch of the manufacturer in Canada or an independent third-party service provider.

If the authorized representative changes mid-process, how are already registered products handled?
The manufacturer must submit a change notification to Health Canada, provide handover proof between the old and new ARs, and ensure the technical documentation and new AR agreement are complete. Product sales cannot be interrupted during the change, but the new AR must have accepted all responsibilities.

Can MDSAP replace the need for an authorized representative?
No. MDSAP certification simplifies the quality system audit but does not replace the legal responsibilities of the AR. Even with MDSAP, foreign manufacturers must still designate a Canadian AR for registration applications and post-market communication.

Disclaimer: This article is compiled based on AIMEILI registration practice database, international medical device registration knowledge base, and public regulatory information. Specific projects should be based on the latest requirements of the target country's regulatory authority and product-specific documentation.